CSIMarket
 



Nanobiotix S a   (NBTX)
Other Ticker:  
 
 



 

What are Nanobiotix S A's Business Segments?



Nanobiotix S.A. is a French clinical-stage nanomedicine company that specializes in the development of cancer therapies. The company's proprietary platform technology, NanoXray, uses nanoparticles to enhance the efficacy of radiotherapy by boosting tumor cell death while preserving healthy tissues.

Segments:

1. Oncology: Nanobiotix's oncology segment develops therapies for various cancer indications, including head and neck cancer, soft tissue sarcoma, prostate cancer, and liver cancer. The company's lead product candidate, NBTXR3, is in late-stage clinical trials for the treatment of head and neck cancer and soft tissue sarcoma.

2. Non-oncology: Nanobiotix is also exploring the potential of its NanoXray platform in non-oncology indications, such as autoimmune diseases and cardiovascular diseases.

Products:

1. NBTXR3: NBTXR3 is a first-in-class radioenhancer designed to improve the efficacy of radiotherapy for cancer patients. The product consists of nanoparticles that are injected directly into tumor cells, where they help to amplify the effects of radiotherapy. NBTXR3 is currently in Phase III clinical trials for the treatment of head and neck cancer and soft tissue sarcoma.

2. NBTX-IO: NBTX-IO is a pre-clinical stage product for the treatment of various solid tumors through the combination of radiotherapy and immuno-oncology. The product is designed to enhance the efficacy of checkpoint inhibitors by increasing the immune system's response to cancer.

Services:

1. Clinical development services: Nanobiotix offers clinical development services to its partners and collaborators, including clinical trial design, patient recruitment, and regulatory strategy.

2. Technology licensing: Nanobiotix licenses its NanoXray platform technology to other companies and research institutions for the development of novel therapeutic applications. The company also offers technical support and expertise to its partners.

3. Manufacturing services: Nanobiotix provides manufacturing services for its products and nanoparticles, including process development, quality control, and scale-up production. The company's state-of-the-art manufacturing facility is located in France and is compliant with international quality and regulatory standards.
   

Nanobiotix S A Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q4
Revenues
(in millions $)
Q4
Income
(in millions $)
(Dec 31 2022)
%
(Profit Margin)
Total 5.35 -63.89 -

Growth rates by Segment Q4
Y/Y Revenue
%
(Dec 31 2022)
Q/Q Revenue
%
Q4
Y/Y Income
%
(Dec 31 2022)
Q/Q Income
%
Total 80.43 % - - -

To get more information on Nanobiotix S A's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com